Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Description

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

Conditions

Warts

Talk to us

Study Overview

On this page

Study Details

Study overview

This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.

Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Condition
Warts
Intervention / Treatment

-

Contacts and Locations

Salt Lake City

University of Utah Midvalley Health Center, Salt Lake City, Utah, United States, 84107

Salt Lake City

VA Salt Lake City Health Care System, Salt Lake City, Utah, United States, 84148

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Must be able to understand and provide written informed consent
  • 2. Age 18 or older
  • 3. Clinical diagnosis of cutaneous warts
  • 4. Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)
  • 1. Untreated cutaneous warts
  • 2. Anogenital warts
  • 3. Oral warts
  • 4. Treatment for cutaneous warts in the past 4 weeks
  • 5. Active acute illness
  • 6. Immunosuppression
  • 7. Known hypersensitivity to HPV vaccination
  • 8. Subjects may not receive any other investigational treatment
  • 9. Pregnancy or planned pregnancy during the study period

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Western Institute for Veterans Research,

Lowell Nicholson, MD, PRINCIPAL_INVESTIGATOR, University of Utah Health Care System

Study Record Dates

2026-12